For instance, combining selumetinib, a MEK inhibitor, with docetaxel did not enhance overall survival in previously treated KRAS mutant non-small-cell lung cancer (NSCLC) patients [46]. Here, MAP2K7 is linked to non-small cell lung carcinoma.